Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) - Leerink Partnrs issued their Q2 2025 earnings estimates for Adagene in a research report issued on Wednesday, August 6th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings of ($0.19) per share for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Adagene's current full-year earnings is ($0.60) per share. Leerink Partnrs also issued estimates for Adagene's Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.68) EPS, FY2027 earnings at ($0.24) EPS, FY2028 earnings at ($0.35) EPS and FY2029 earnings at ($0.38) EPS.
Separately, Leerink Partners began coverage on shares of Adagene in a research note on Wednesday, August 6th. They set an "outperform" rating and a $7.00 target price for the company.
Read Our Latest Stock Report on ADAG
Adagene Price Performance
Shares of NASDAQ ADAG traded up $0.07 during trading hours on Friday, hitting $2.36. 70,307 shares of the stock were exchanged, compared to its average volume of 63,040. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.30 and a quick ratio of 2.30. The company's 50 day moving average is $1.95 and its 200 day moving average is $1.81. Adagene has a one year low of $1.33 and a one year high of $3.58.
Institutional Trading of Adagene
Several institutional investors have recently made changes to their positions in ADAG. Kamunting Street Capital Management L.P. bought a new stake in shares of Adagene in the 4th quarter worth about $251,000. Fifth Lane Capital LP acquired a new stake in shares of Adagene during the 4th quarter worth about $54,000. Finally, Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Adagene during the 1st quarter worth about $29,000. 9.51% of the stock is currently owned by institutional investors and hedge funds.
Adagene Company Profile
(
Get Free Report)
Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
See Also
Before you consider Adagene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adagene wasn't on the list.
While Adagene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access